X0306 4 2021-03-01 0001682852 Moderna, Inc. MRNA 0001690927 Zaks Tal Zvi C/O MODERNA, INC. 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 1 Chief Medical Officer Common Stock 2021-03-01 4 M 0 5000 12.21 A 5000 D Common Stock 2021-03-01 4 M 0 5000 14.22 A 10000 D Common Stock 2021-03-01 4 S 0 2201 146.68 D 7799 D Common Stock 2021-03-01 4 S 0 1986 147.71 D 5813 D Common Stock 2021-03-01 4 S 0 700 149.00 D 5113 D Common Stock 2021-03-01 4 S 0 1039 149.79 D 4074 D Common Stock 2021-03-01 4 S 0 600 150.86 D 3474 D Common Stock 2021-03-01 4 S 0 900 152.01 D 2574 D Common Stock 2021-03-01 4 S 0 753 154.34 D 1821 D Common Stock 2021-03-01 4 S 0 600 155.69 D 1221 D Common Stock 2021-03-01 4 S 0 771 156.49 D 450 D Common Stock 2021-03-01 4 S 0 450 157.29 D 0 D Stock Option (Right to Buy) 12.21 2021-03-01 4 M 0 5000 0 D 2027-02-23 Common Stock 5000 1478 D Stock Option (Right to Buy) 14.22 2021-03-01 4 M 0 5000 0 D 2028-02-28 Common Stock 5000 45175 D The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $146.31 to $147.20. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $147.32 to $148.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $148.33 to $149.33. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $149.34 to $150.24. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $150.59 to $151.14. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $151.73 to $152.67. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $153.99 to $154.98. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $155.10 to $155.92. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $156.13 to $157.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.20 to $157.49. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. 25% of this option vested and became exercisable on February 22, 2018 with the remainder vesting in 12 equal quarterly installments thereafter. 25% of this option vested and became exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter. /s/ Brian Sandstrom, as Attorney-in-Fact 2021-03-02